Search hospitals > California > Roseville
Sutter Cancer Centers Radiation Oncology Services-Roseville
Claim this profileRoseville, California 95661
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
135 reported clinical trials
9 medical researchers
Summary
Sutter Cancer Centers Radiation Oncology Services-Roseville is a medical facility located in Roseville, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Sutter Cancer Centers Radiation Oncology Services-Roseville is involved with conducting 135 clinical trials across 281 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Ari Baron, MDAlta Bates Summit Medical Center-Herrick Campus7 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
28 reported clinical trials
66 drugs studied
Christopher JonesSutter Medical Center Sacramento3 years of reported clinical research
Studies Cancer
Studies Prostate Cancer
23 reported clinical trials
62 drugs studied
Deepti BehlCalifornia Pacific Medical Center-Pacific Campus4 years of reported clinical research
Studies Lung Cancer
Studies Non-Small Cell Lung Cancer
16 reported clinical trials
49 drugs studied
Kristie A. BobolisAlta Bates Summit Medical Center-Herrick Campus1 year of reported clinical research
Studies Breast Cancer
Studies Cancer
10 reported clinical trials
27 drugs studied
Clinical Trials running at Sutter Cancer Centers Radiation Oncology Services-Roseville
Breast Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Squamous Cell Carcinoma
Cancer
Pancreatic Cancer
Meningioma
Prostate Cancer
Renal Cell Carcinoma
Multiple Myeloma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Whole Brain Radiotherapy + Stereotactic Radiosurgery
for Brain Metastasis
This phase III trial compares the effect of adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery versus stereotactic radiosurgery alone in treating patients with cancer that has spread to the brain and come back in other areas of the brain after earlier stereotactic radiosurgery. Hippocampus avoidance during whole-brain radiation therapy decreases the amount of radiation that is delivered to the hippocampus, which is a brain structure that is important for memory. The medicine memantine is also often given with whole brain radiation therapy because it may decrease the risk of side effects of radiation on thinking and memory. Stereotactic radiosurgery delivers a high dose of radiation only to the small areas of cancer in the brain and avoids the surrounding normal brain tissue. Adding whole brain radiotherapy with hippocampal avoidance and memantine to stereotactic radiosurgery may be effective in shrinking or stabilizing cancer that has spread to the brain and returned in other areas of the brain after receiving stereotactic radiosurgery.
Recruiting2 awards Phase 312 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Sutter Cancer Centers Radiation Oncology Services-Roseville?
Sutter Cancer Centers Radiation Oncology Services-Roseville is a medical facility located in Roseville, California. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Adenocarcinoma, Recurrence and other specialties. Sutter Cancer Centers Radiation Oncology Services-Roseville is involved with conducting 135 clinical trials across 281 conditions. There are 9 research doctors associated with this hospital, such as Ari Baron, MD, Christopher Jones, Deepti Behl, and Kristie A. Bobolis.